Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.

Rorick-Kehn LM, Witcher JW, Lowe SL, Gonzales CR, Weller MA, Bell RL, Hart JC, Need AB, McKinzie JH, Statnick MA, Suico JG, McKinzie DL, Tauscher-Wisniewski S, Mitch CH, Stoltz RR, Wong CJ.

Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu036. doi: 10.1093/ijnp/pyu036.

2.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.

Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, Jimenez A, Pedregal C, Mitch CH, Knopp KL, Anderson WH, Cramer JW, McKinzie DL.

Neuropharmacology. 2014 Feb;77:131-44. doi: 10.1016/j.neuropharm.2013.09.021. Epub 2013 Sep 23.

PMID:
24071566
3.

Mice lacking δ-opioid receptors resist the development of diet-induced obesity.

Czyzyk TA, Romero-Picó A, Pintar J, McKinzie JH, Tschöp MH, Statnick MA, Nogueiras R.

FASEB J. 2012 Aug;26(8):3483-92. doi: 10.1096/fj.12-208041. Epub 2012 May 16.

4.

kappa-Opioid receptors control the metabolic response to a high-energy diet in mice.

Czyzyk TA, Nogueiras R, Lockwood JF, McKinzie JH, Coskun T, Pintar JE, Hammond C, Tschöp MH, Statnick MA.

FASEB J. 2010 Apr;24(4):1151-9. doi: 10.1096/fj.09-143610. Epub 2009 Nov 16.

5.

Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.

Takeuchi K, Holloway WG, Mitch CH, Quimby SJ, McKinzie JH, Suter TM, Statnick MA, Surface PL, Emmerson PJ, Thomas EM, Siegel MG.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.

PMID:
17980586
6.

In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.

Need AB, McKinzie JH, Mitch CH, Statnick MA, Phebus LA.

Life Sci. 2007 Oct 13;81(17-18):1389-96. Epub 2007 Sep 19.

PMID:
17935738
7.

Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.

Takeuchi K, Holloway WG, McKinzie JH, Suter TM, Statnick MA, Surface PL, Emmerson PJ, Thomas EM, Siegel MG, Matt JE, Wolfe CN, Mitch CH.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.

PMID:
17720493
8.

Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists.

Emmerson PJ, McKinzie JH, Surface PL, Suter TM, Mitch CH, Statnick MA.

Eur J Pharmacol. 2004 Jun 28;494(2-3):121-30.

PMID:
15212965
9.
10.

Development of rapid tolerance to ethanol-stimulated serotonin release in the ventral hippocampus.

Bare DJ, McKinzie JH, McBride WJ.

Alcohol Clin Exp Res. 1998 Sep;22(6):1272-6.

PMID:
9756042
11.

Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells.

Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL.

Anticancer Res. 1998 Mar-Apr;18(2A):823-8.

PMID:
9615726
12.
13.

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol.

Stark MJ, Burke YD, McKinzie JH, Ayoubi AS, Crowell PL.

Cancer Lett. 1995 Sep 4;96(1):15-21.

PMID:
7553603

Supplemental Content

Loading ...
Support Center